Month: February 2018

ICABELL, a new boost to the internationalization of IDIBELL’s research

The Bellvitge Biomedical Research Institute has been awarded 176,734€ in order to carry out the “ICABELL – Internationalization of biomedical research on the Bellvitge Campus” project, whose main researcher is Dr. Josep Manuel Menchón. The aid is part of the Call for Boosting Actions: Europe Networks and Managers – Europe Technology Centers 2017, which is …

ICABELL, a new boost to the internationalization of IDIBELL’s research Read More »

Nobel Laureate Erwin Neher visits IDIBELL

The winner of the 1991 Nobel Prize for Medicine visits the institute and talks to its younger researchers Last Wednesday, February 21st, the Bellvitge Biomedical Research Institute (IDIBELL) welcomed professor Erwin Neher, Nobel Prize in Physiology or Medicine in 1991, to participate in an informal meeting with the pre and postdoctoral researchers of the institute. …

Nobel Laureate Erwin Neher visits IDIBELL Read More »

RAC1 protein could be a new therapeutic target to fight neurodegeneration in Parkinson’s disease

A new research study reveals RAC1 protein could be a new therapeutic target to study the molecular mechanisms related to the neurodegenerative processes in Parkinson’s disease. The study, published in the online edition of the journal Molecular Neurobiology, is led by Antonella Consiglio, researcher at the Faculty of Medicine and Health Sciences of the University of Barcelona, the …

RAC1 protein could be a new therapeutic target to fight neurodegeneration in Parkinson’s disease Read More »

ADmit Therapeutics becomes a new IDIBELL spin-off

ADmit Therapeutics, S.L. has become a new spin-off company of Bellvitge Biomedical Research Institute (IDIBELL) after acquiring a license agreement with IDIBELL and University of Barcelona to develop a test for an early Alzheimer’s disease (AD) detection. The company is currently supported by IDIBELL, Bellvitge University Hospital (HUB) and ACCIÓ (Generalitat de Catalunya). “Our main …

ADmit Therapeutics becomes a new IDIBELL spin-off Read More »

Scientists prove the implication of an amino acid transporter in age-related deafness

The CIBERER U730 and U731 units, led respectively by Virginia Nunes (IDIBELL, UB) and Manuel Palacín (IRBB, UB) have just published in eLife a study carried out in collaboration with the U761 units (Isabel Varela-Nieto, CSIC / UAM) and U716 (Mara Dierssen, CRG), as well as with international groups, Dr. Meritxell Espino (Sidra Medicine, Qatar) and Dr. …

Scientists prove the implication of an amino acid transporter in age-related deafness Read More »

The IT-LIVER European consortium expands TGF-beta knowledge in liver cancer

The research of the TGF-beta and cancer group of the Bellvitge Biomedical Research Institute (IDIBELL) within the IT-LIVER (Inhibiting TGF-beta in liver diseases) consortium, a collaborative European action coordinated by Dr. Isabel Fabregat, has led to three new impact publications that offer new insights into the molecular mechanisms associated with the cytokine TGF-beta in liver …

The IT-LIVER European consortium expands TGF-beta knowledge in liver cancer Read More »

Àlex Vaquero is awarded 200,000 euros from Worldwide Cancer Research to better understand the origin of cancer

Dr. Àlex Vaquero, leader of the chromatin biology research group of the Bellvitge Biomedical Research Institute (IDIBELL), has been awarded one of the prestigious grants from the Worldwide Cancer Research organization,  worth 200,000 euros. The grant will fund a new project of this basic research group focused on the study of the mechanisms of tumor …

Àlex Vaquero is awarded 200,000 euros from Worldwide Cancer Research to better understand the origin of cancer Read More »

Scroll to Top